Published in Science on March 05, 2009
Targeted capture and massively parallel sequencing of 12 human exomes. Nature (2009) 33.96
International network of cancer genome projects. Nature (2010) 20.35
Pancreatic cancer. Lancet (2004) 11.63
Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res (2011) 10.99
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet (2010) 5.48
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol (2010) 5.35
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
The predictive capacity of personal genome sequencing. Sci Transl Med (2012) 4.64
Whole genomes redefine the mutational landscape of pancreatic cancer. Nature (2015) 4.01
Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol (2012) 4.00
Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol (2009) 3.67
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol (2015) 3.19
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Susceptibility pathways in Fanconi's anemia and breast cancer. N Engl J Med (2010) 2.79
The genetic contribution to non-syndromic human obesity. Nat Rev Genet (2009) 2.70
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med (2014) 2.41
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res (2011) 2.27
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
Architecture of inherited susceptibility to common cancer. Nat Rev Cancer (2010) 2.14
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology (2009) 2.08
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol (2010) 2.07
PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res (2010) 2.07
Design of association studies with pooled or un-pooled next-generation sequencing data. Genet Epidemiol (2010) 2.06
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet (2012) 1.84
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology (2014) 1.78
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol (2015) 1.73
Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology (2011) 1.70
Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res (2009) 1.65
High prevalence of BRCA1 and BRCA2 germline mutations with loss of heterozygosity in a series of resected pancreatic adenocarcinoma and other neoplastic lesions. Clin Cancer Res (2013) 1.63
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst (2010) 1.57
Update on familial pancreatic cancer. Adv Surg (2010) 1.54
Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res (2011) 1.52
Genome-wide association study of pancreatic cancer in Japanese population. PLoS One (2010) 1.50
Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep (2009) 1.50
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing. Clin Cancer Res (2012) 1.47
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med (2011) 1.46
Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nat Med (2015) 1.45
Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther (2011) 1.45
Genetic susceptibility to pancreatic cancer. Mol Carcinog (2012) 1.36
Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol (2013) 1.34
A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet (2010) 1.34
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet (2015) 1.34
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34
An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One (2013) 1.33
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.32
Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer. Cancer Discov (2013) 1.32
PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol (2012) 1.30
Familial pancreatic cancer--current knowledge. Nat Rev Gastroenterol Hepatol (2012) 1.27
Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci (2012) 1.26
Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer (2012) 1.21
Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. Am J Clin Pathol (2014) 1.21
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut (2011) 1.20
PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer (2011) 1.18
Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int (2011) 1.17
Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2010) 1.17
Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas (2013) 1.15
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res (2013) 1.09
German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer (2011) 1.06
Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer (2011) 1.05
PALB2 and breast cancer: ready for clinical translation! Appl Clin Genet (2013) 1.03
Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol (2014) 1.03
Pancreatic cancer screening. Gastroenterol Clin North Am (2012) 1.02
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.01
Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget (2015) 1.01
Disease-specific prospective family study cohorts enriched for familial risk. Epidemiol Perspect Innov (2011) 1.01
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses. Biochim Biophys Acta (2014) 1.01
A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. J Med Genet (2012) 1.01
Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int (2013) 1.01
PALB2 mutations in German and Russian patients with bilateral breast cancer. Breast Cancer Res Treat (2010) 1.01
The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting. J Pathol (2010) 1.00
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol (2015) 0.99
A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res (2010) 0.98
Novel methylation biomarker panel for the early detection of pancreatic cancer. Clin Cancer Res (2013) 0.98
Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. Genome Med (2012) 0.97
Human correlates of provocative questions in pancreatic pathology. Adv Anat Pathol (2012) 0.97
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med (2014) 0.97
Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated. Eur J Hum Genet (2011) 0.97
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet (2011) 0.96
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol (2015) 0.95
Genetic predisposition to pancreatic cancer. World J Gastroenterol (2014) 0.94
Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol (2012) 0.94
Multiple small "imaging" branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer (2013) 0.94
Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery. J Cell Biol (2014) 0.94
Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Clin Cancer Res (2015) 0.93
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell (2006) 7.33
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet (2008) 3.40
Medicine. The future of personal genomics. Science (2007) 3.36
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
International network of cancer genome projects. Nature (2010) 20.35
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36